Mobidiag announced today that it has initiated the development of a sepsis assay on the new Novodiag^® system thanks to a €1.5 million loan from Business Finland.

Mobidiag  has successfully completed a 4 million euros funding supported by the Finnish investment service company Springvest Oy (former Kansalaisrahoitus) for its global business development, including its capacity to answer growing needs for the new Novodiag^® solution.

CE-IVD marking of Amplidiag^® CarbaR+MCR, a molecular test allowing detection of the main carbapenemase-producing organisms and colistin resistance markers in one single test.